Key facts
- It has raised $18.3M; the latest was Early Stage VC ($8.3M) in Jun 2025.
- Notable investors include SMBC Venture Capital, Mizuho Capital, Japan Finance Corporation, MPower Partners, Asahi Kasei — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Cyto-Facto
- ·The full record, as it builds
Funding rounds
No funding rounds for Cyto-Facto are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cyto-Facto
Operator of a cell therapy research and development center intended to develop quality standards for cell preparations used in gene and cell therapy. The company manufactures commercial CAR-T cell therapy products, which include mesenchymal stem cells, and offers services related to management systems development, sales, and process development, enabling clients to bring gene and cell therapies to patients in a timely and reliable manner.
- Sector
- Healthcare
- HQ
- Kobe, Japan
- Founded
- 2022
- Employees
- 100
- Website
- cytofacto.com/
- Ownership
- Privately Held (backing)
Cyto-Facto doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cyto-Facto shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cyto-Facto in its N-PORT filings yet. We sweep new filings monthly.